

1 **Improved resolution of influenza vaccination**

2 **responses with high-throughput live virus**

3 **microneutralisation**

4 Lorin Adams^{*,1}, Phoebe Stevenson-Leggett^{*,2}, Jia Le Lee³, James Bazire², Giulia
5 Dowgier², Agnieszka Hobbs², Chloë Roustan⁴, Annabel Borg⁴, Christine Carr¹, Silvia
6 Innocentin³, Louise MC Webb³, Callie Smith⁴, Philip Bawumia⁴, Nicola Lewis¹, Nicola
7 O'Reilly⁴, Svend Kjaer⁴, Michelle A Linterman³, Ruth Harvey^{*,1}, Mary Y Wu^{*,2}, and
8 Edward J Carr^{*,4,5}✉

9 * These authors contributed equally to this work.

10 ¹ Worldwide Influenza Centre, The Francis Crick Institute, 1 Midland Road, London NW1 1AT,
11 UK

12 ² COVID Surveillance Unit, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK

13 ³ Immunology Program, Babraham Institute, Cambridge, UK

14 ⁴ The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK

15 ⁵ UCL Centre for Kidney & Bladder Health, Royal Free Hospital, Rowland Hill Street, London
16 NW3 2PF, UK

17 ✉ Correspondence: [Edward J Carr <edward.carr@ucl.ac.uk>](mailto:edward.carr@ucl.ac.uk)

18 Word count 2502

19

influenza HAI vs HTS

20 **Abstract**

21 Influenza remains a significant threat to human and animal health. Assessing serological
22 protection against influenza has relied upon haemagglutinin inhibition assays, which are used to
23 gauge existing immune landscapes, seasonal vaccine decisions and in systems vaccinology
24 studies. Here, we adapt our high-throughput live virus microneutralisation assay for SARS-CoV-
25 2, benchmark against haemagglutinin inhibition assays, and report serological vaccine
26 responsiveness in a cohort of older (>65yo) community dwelling adults (n=73), after the
27 adjuvanted 2021-22 Northern Hemisphere quadrivalent vaccine. We performed both assays
28 against all four viruses represented in the vaccine (A/Cambodia/H3N2/2020,
29 A/H1pdm/Victoria/2570/2019, B/Yamagata/Phuket/2013, BVIC/Washington/02/2019), using
30 sera drawn on days 0 [range: d-28 to d0], 7 [d6-10] and 182 [d161-196] with respect to
31 vaccination. We found population-level concordance between the two assays (Spearman's
32 correlation coefficient range 0.48-0.88; all $P \leq 1.4 \times 10^{-5}$). The improved granularity of
33 microneutralisation was better able to estimate fold-changes of responses, and quantify the
34 inhibitory effect of pre-existing antibody. Our high-throughput method offers an alternative
35 approach to assess influenza-specific serological responses with improved resolution.

36 **Introduction**

37 Influenza causes an estimated 389,000 deaths a year (1). Whilst annually updated multi-valent
38 vaccines reduce this burden, better laboratory methods offering rapid, granular evaluation of the
39 neutralising antibody response to these vaccines could further minimise this. Firstly, by
40 facilitating refined yearly strain selection through high resolution quantification of the pre-existing
41 antibody landscape. Secondly, by rapid, robust comparison between vaccine platforms, both
42 existing (protein, adjuvanted protein, live-attenuated virus, or split virion), and upcoming (mRNA,
43 and others). Thirdly, by providing a continuous response variable for systems vaccinology
44 studies, to better leverage multi-modal high-dimensional and longitudinal datasets, themselves

It is made available under a [CC-BY 4.0 International license](#) .

influenza HAI vs HTS

45 generated at significant cost and resource. Finally, by allowing prompt re-evaluation of human
46 population immunity when an antigenically shifted influenza virus emerges, such as H5N1.
47 Currently, the haemagglutinin inhibition (HAI) assay is used to evaluate existing population-level
48 immunity to guide annual vaccine strain selection, to confirm immunogenicity of these updated
49 preparations, and as a correlate of protection. HAI assays are largely unchanged since first
50 described in the 1940s (2,3): they are scalable, require minimal specialist laboratory equipment,
51 but do not directly measure neutralising antibody, a critical effector arm of immunity. Virus will
52 agglutinate red blood cells, naturally decorated with sialic acid, the ligand for influenza's HA.
53 Agglutination is inhibited by sera containing HA-specific antibodies. Live-virus neutralisation
54 assays for influenza have existed for decades (4), but have to-date not been capable of
55 displacing the HAI assay, largely due to limitations in the number of sera processed and their
56 relative complexity.

57 Results and Discussion

58 Here, we perform a head-to-head comparison of paired HAI, and a newly developed high-
59 throughput live-virus microneutralisation (LV-N) assay. We demonstrate that large scale
60 microneutralisation assays (see Materials and Methods) of 4 influenza strains are both feasible,
61 and offer enhanced resolution. Adapting our SARS-CoV-2 approach, retains a similar
62 throughput of ~1,000-1,500 sera for 3 strains per week. We report sera from the AgeVAX study,
63 an observational study of influenza vaccine responses in 73 community dwelling older adults
64 (>65yo), with venepuncture on days 0 [range: d-28 to d0], 7 [d6-10] and 182 [d161-196] post-
65 vaccination (**Table 1, Fig 1A**).

66 We first confirm increased antibody titres for all 4 influenza strains at d7 after administration of
67 the 2021-22 vaccine using HAI (d7 vs d0 Wilcoxon $P < 0.015$ for all strains, **Fig 1B**). Between
68 paired sera, we find waning from d7 to d182 for two of the four immunised strains

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

influenza HAI vs HTS

69 (A/Cambodia/H3N2/2020 $P=0.19$; A/H1pdm/Victoria/2570/2019 $P=6.1\times 10^{-4}$;
70 B/Yamagata/Phuket/2013 $P=0.16$; BVIC/Washington/02/2019 $P=0.024$, **Fig 1B**). We next
71 repeated this immunogenicity assessment using our newly developed LV-N assay (**Fig 1C**). The
72 boosting effect of vaccination is, once again, clear (d7 vs d0 $P<0.002$ for all strains, **Fig 1C**).
73 With the LV-N assay, three of the four immunised strains showed significant waning between d7
74 and d182 A/Cambodia/H3N2/2020 $P=0.4$; A/H1pdm/Victoria/2570/2019 $P=2.8\times 10^{-4}$;
75 B/Yamagata/Phuket/2013 $P=0.004$; BVIC/Washington/02/2019 $P=2.9\times 10^{-4}$. The quantitative
76 nature of the LV-N assays offers improved resolution of the fold-change of the acute response
77 (in the AgeVax study, the fold-change in titres d7/d0), with geometric mean fold-changes [95%
78 confidence intervals] for LV-N estimating smaller reductions boosts with less uncertainty
79 between these visits, when compared with HAI (**Fig 1D**). Furthermore, the waning (d182/d7) of
80 B/Yamagata reached statistical significance only within the LV-N dataset (**Figs 1B & 1C**).

81 Thirdly, we plotted pairwise comparisons between HAI and LV-N for each strain at each of the
82 three venepuncture visits (**Fig 2A**). Overall, the two assays showed a strong positive correlation
83 according to their Spearman's correlation coefficients. Considering differences between strains,
84 B/Yamagata showed relatively weaker correlations than the other 3 strains. Next, considering
85 differences over the 3 timepoints, the between-assay correlation for B/Victoria was weakest at
86 d182, but no other strains showed marked differences over time.

87 Despite the high concordance between assays at a population-level, we noted that for a given
88 HAI titre, the range of corresponding LV-N results was large: for example, an HAI titre of 20 at
89 baseline (d0) corresponded to an LV-N range of 43-1004 for influenza A/H1. This 23-fold
90 difference suggests that immunologically important differences in vaccine responses are
91 aggregated into discrete HAI values. To address the question of whether LV-N offered
92 improved sensitivity for biologically relevant heterogeneity over HAI, we returned to the
93 observation that pre-existing antibody limits the fold-induction of antibody after vaccination (5).

influenza HAI vs HTS

94 Using HAI, we found that we could observe this negative relationship between higher baseline
95 titres and lower fold-changes (d7/d0) for only FluA/H1pdm (P=0.029), with the other strains
96 showing non-significant trends (**Fig 3A**). Repeating this comparison with LV-N, we found
97 moderately strong negative correlations between pre-existing neutralising antibody and peak
98 fold-change (d7/d0) for all variants (all P<0.009, **Fig 3B**). Coupling longitudinal LV-N-derived
99 serological data with multi-modal datasets promises to unlock new potentials in systems
100 vaccination, examining both peak and waned responses.

101 There are some limitations to our study. This single centre study enrolled older healthy adults,
102 likely to mount a memory response, recalling both previously haemagglutinin-experienced B
103 cells and recruiting naive B cells. It is plausible that a primary influenza vaccine response might
104 be alternatively performant between these assays, particularly if significant IgM is produced,
105 likely to perform well at HAI. Additionally, our live-virus microneutralisation approach reflects
106 serological neutralisation of both HA and neuraminidase, whereas HAI does not assay NA-
107 directed neutralisation. Other implementations of microneutralisation assays use alternative
108 readouts for infection: for example, the WHO protocol uses an ELISA for nucleoprotein on fixed
109 MDCK cells (reporting the lowest dilution at which the OD405 is below the midpoint of OD405 of
110 virus-only and cell-only controls) (6), and a recently described next-generation sequencing
111 assay testing infectivity/neutralisation of many DNA-barcoded viruses in parallel (7). Whilst, we
112 have not directly compared with these methods, the DNA-barcoding approach can only find HA-
113 related neutralisation, and the WHO neutralisation assay reports discrete rather than continuous
114 data.

115 In summary, we have shown that high-throughput live-virus microneutralisation assays are non-
116 inferior to HAI with strong correlations at population-levels. Further, we find that the continuous
117 titre values returned by LV-N allow for finer dissection of vaccine responses, that are obfuscated
118 by HAI. High-throughput influenza LV-N therefore has the potential to be a catalyst for rapid,

influenza HAI vs HTS

119 robust assessment of existing antibody landscapes, new vaccine strain formulations, a step-
120 change in systems vaccinology, and a facet of laboratory-based pandemic preparedness.

121 **Materials and Methods**

122 **Study design, serum collection and ethics**

123 The immune responses to vaccines in older persons study (AgeVax) enrolled community
124 dwelling older adults already enrolled within the NIHR Cambridge BioResource to assess their
125 response to seasonal influenza vaccine. AgeVax was approved by the Yorkshire & The Humber
126 - South Yorkshire Research Ethics Committee (IRAS 277259, REC 20/YH/0101), and
127 sponsored by the Babraham Institute, Cambridge. Healthy participants were enrolled if they
128 were planning to receive the seasonal influenza vaccine as part of their routine care (in the UK,
129 influenza vaccine is offered to all >65yo), were able to attend for consenting and venepuncture,
130 and carried at least 1 allele of *HLADR*0701*, *HLADR*0401* or *HLADR*1101* (determined by
131 single nucleotide polymorphism typing using the UK Biobank v2.1 Axiom array). Controlled
132 comorbidities such as hypertension or hypercholesterolaemia were not exclusion criteria.
133 Concomitant medications and comorbidities are not available for research purposes.

134 Venepuncture was performed up to 28 days pre-vaccination and on days 6-10, and 161-196
135 post vaccination. All participants received the adjuvanted quadrivalent influenza vaccine
136 (Seqirus UK Ltd) via intramuscular injection. Blood was collected into silica-coated serum tubes
137 and centrifuged at 2000rpm for 5 minutes and stored in aliquots at -80C. These sera were
138 provided to the Francis Crick Institute for influenza assays described below.

139 **Cells and viruses**

140 MDCK cells expressing the SIAT1 gene (MDCK-SIAT1) were maintained under selection in
141 DMEM containing 1mg/ml Geneticin (G418) Sulphate (Strattech Scientific APE2513) and 1%

influenza HAI vs HTS

142 Penicillin/Streptomycin (Sigma-Aldrich). Cells were seeded in DMEM containing 1%
143 Penicillin/Streptomycin into 384-well cell culture microplates (Griener Bio-One Ltd) 18-20 hours
144 prior to use in live-virus microneutralisation assays.

145 All influenza virus isolates used in this study were propagated in the allantoic cavity of 10-day-
146 old embryonated hens' eggs at 35°C for 48 hours.

147 **Hemagglutinin inhibition assays for influenza**

148 Haemagglutination and haemagglutinin inhibition (HAI) assays were performed according to
149 standard methods using suspensions of guinea pig RBCs (1.0% v/v) for A(H3N2) viruses and
150 turkey RBCs (0.75% v/v) for A(H1N1)pdm09 and type B viruses with all serum samples pre-
151 treated with receptor-destroying enzyme (RDE) from *Vibrio cholera* (8). Four haemagglutination
152 units were used in all HAI assays. For A(H3N2) viruses, haemagglutination and HAI assays
153 were conducted in the presence of 20 nM oseltamivir carboxylate (9).

154 **Live-virus microneutralisation assays for influenza**

155 To perform high-throughput live virus microneutralisation assays for influenza we adapted our
156 existing approach for SARS-CoV-2 neutralisation (10–12). MDCK-SIAT1 cells at 80%
157 confluency were infected with selected influenza isolates in 384-well format, in the presence of
158 10-fold serial dilutions of participant serum samples, diluted in DMEM containing 1%
159 Penicillin/Streptomycin. After 24 hours incubation at 37°C, cells were fixed using 4%
160 formaldehyde (v/v), permeabilised with 0.2% TritonX-100 with 3% BSA in PBS (v/v), and stained
161 for Influenza nucleoprotein (NP) using Biotin-labelled-clone-2-8C antibody produced in-house in
162 conjunction with an Alexa488-Streptavidin (Invitrogen S32354) for influenza A isolates, or the
163 mouse monoclonal B017 (Abcam, ab20711) in conjunction with an Alexa488 conjugated Goat
164 anti-Mouse secondary (ThermoFisher, A21141) for influenza B isolates. Cellular DNA was
165 stained using DAPI. Whole-well imaging at 5x magnification was carried out using an Opera

influenza HAI vs HTS

166 Phenix (Perkin Elmer) and fluorescent areas calculated using the Phenix-associated software
167 Harmony (Perkin Elmer). Virus inhibition by patient serum samples was estimated from the
168 measured area of infected cells/total area occupied by all cells in each well and then expressed
169 as percentage of maximal (virus only control wells). Infected cells were identified by presence of
170 Influenza NP staining. The inhibitory profile of each serum sample was estimated by fitting a 4-
171 parameter dose response curve executed in SciPy. Neutralising antibody titres are reported as
172 the fold-dilution of serum required to inhibit 50% of viral replication (IC_{50}), and are further
173 annotated if they lie above the quantitative range ($>40,000$), below the quantitative range (<40)
174 but still within the qualitative range (i.e. partial inhibition is observed but a dose-response curve
175 cannot be fitted because it does not sufficiently span the IC_{50}), or if they show no inhibition at all.
176 Viral isolates used in this study: A/Cambodia/e0826360/2020 H3N2, IVR-215
177 (A/Victoria/2570/2019) H1pdm, B/Phuket/3073/2013, B/Washington/02/2019.

178 **Data curation and analyses**

179 HAI and live-virus microneutralisation titres were associated with anonymized metadata using R
180 (v 4.2.2) and *tidyverse* (v 1.3.2) (13). Plots were generated using *ggplot2* (v 3.4.2), with
181 *stat_summary()* to add geometric means or medians, as indicated in the figure legends. To plot
182 HAI titres, sera with no inhibition were re-coded as 2.5. To plot LV-N titres, sera with either no
183 inhibition of viral entry, or qualitative inhibition below the quantitative range (40-40,000), or
184 inhibition greater than the quantitative range were re-coded as 5, 10 or 80,000 respectively. HAI
185 and LV-N results were compared using two-tailed paired Wilcoxon tests, as implemented in the
186 *rstatix* package, and resulting P values were plotted *ggpubr::geom_bracket()* and
187 *ggtext::geom_richtext()*. Bias corrected 95% confidence intervals for fold-changes in HAI and
188 LV-N were calculated from 1000 bootstraps generated with the *infer* package (14). For
189 correlation between HAI and LV-N, Spearman's correlation was used without censoring data

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

influenza HAI vs HTS

190 above or below the quantitative ranges of HAI or LV-N. Anonymised data and R code are freely
191 available via github:https://github.com/EdjCarr/AgeVax_HAI_LVN

192 **Acknowledgements**

193 The NIHR Cambridge Biomedical Research Center (BRC) is a partnership between Cambridge
194 University Hospitals NHS Foundation Trust and the University of Cambridge, funded by the
195 National Institute for Health Research (NIHR). We thank all NIHR Cambridge BRC volunteers
196 for their participation and thank the NIHR Cambridge BRC staff for their contribution in
197 coordinating the vaccinations and venepuncture. We would like to thank Marna Roos, Gita
198 Mistry, Nicola Bex, Natasha Bowyer Irvine at the Francis Crick Institute and Heather Bath at the
199 Babraham Institute. MAL is a Lister Institute Prize Fellow. EJC is supported by a Medical
200 Research Council Clinician Scientist Fellowship (MR/X006751/1). This work was supported by
201 the NIHR Cambridge BRC, the Dunhill Medical Trust (RPGF1910/223 to MAL), the
202 Biotechnology and Biological Sciences Research Council (BBS/E/B/000C0427,
203 BBS/E/B/000C0428, and the Campus Capability Core Grant to the Babraham Institute), the
204 Medical Research Council (MR/X006751/1 to EJC), a UKRI Frontier award (EP/X022382/1 to
205 MAL), in part funded by the NIH Centres of Excellence in Influenza Research and Response
206 program Penn-CEIRR contract (75N93021C00015), and by the Francis Crick Institute which
207 receives its core funding from Cancer Research UK (CC1114, CC2230, CC0102), the UK
208 Medical Research Council (CC1114, CC2230, CC0102), and the Wellcome Trust (CC1114,
209 CC2230, CC0102). The co-first and co-last authors contributed equally and are at liberty to list
210 these authorships in any order on their curriculum vitae.

211 **Author contributions**

212 LA: Conceptualization, Methodology, Investigation

213 PSL: Conceptualization, Methodology, Investigation

influenza HAI vs HTS

- 214 JLL: Project administration, Methodology, Investigation
- 215 JB: Methodology, Investigation
- 216 GD: Methodology, Investigation
- 217 AH: Methodology, Investigation
- 218 CR: Resources
- 219 AB: Resources
- 220 CC: Resources
- 221 SI: Methodology, Investigation
- 222 LMCW: Methodology, Investigation
- 223 CS: Resources
- 224 PB: Resources
- 225 NL: Resources, Supervision
- 226 NO'R: Resources, Supervision
- 227 SK: Resources, Supervision
- 228 MAL: Conceptualization, Funding acquisition, Supervision, Writing – review & editing
- 229 RH: Conceptualization, Funding acquisition, Investigation, Supervision, Writing – review &
230 editing
- 231 MYW: Conceptualization, Funding acquisition, Investigation , Supervision, Writing – review &
232 editing

influenza HAI vs HTS

233 EJC: Conceptualization, Data Curation, Formal Analysis, Visualisation, Writing – original draft, ,
234 Writing – review & editing

235 **Role of the funding source**

236 The funders of the study had no role in study design, data collection, data analysis, data
237 interpretation, or writing of the report. The corresponding authors had full access to all the data
238 and the final responsibility to submit for publication.

239 **Declaration of interests**

240 All authors declare no competing interests.

241 **References**

- 242 1. Paget J, Spreeuwenberg P, Charu V, Taylor RJ, Iuliano AD, Bresee J, et al.
243 [Global mortality associated with seasonal influenza epidemics: New burden estimates](#)
244 [and predictors from the GLaMOR Project](#). Journal of Global Health. 2019
245 Dec;9(2):020421.
- 246 2. Salk JE. A Simplified Procedure for Titrating Hemagglutinating Capacity of
247 Influenza-Virus and the Corresponding Antibody. The Journal of Immunology [Internet].
248 1944 Aug 1;49(2):87–98. Available from:
249 [https://journals.aai.org/jimmunol/article/49/2/87/100144/A-Simplified-Procedure-for-](https://journals.aai.org/jimmunol/article/49/2/87/100144/A-Simplified-Procedure-for-Titrating)
250 [Titrating](#)
- 251 3. Hirst GK. [THE QUANTITATIVE DETERMINATION OF INFLUENZA VIRUS AND](#)
252 [ANTIBODIES BY MEANS OF RED CELL AGGLUTINATION](#). The Journal of
253 Experimental Medicine. 1942 Jan 1;75(1):49–64.
- 254 4. Bachmann MF, Ecabert B, Kopf M. [Influenza virus: a novel method to assess](#)
255 [viral and neutralizing antibody titers in vitro](#). Journal of Immunological Methods. 1999
256 May 27;225(1-2):105–11.

influenza HAI vs HTS

- 257 5. Tsang JS, Schwartzberg PL, Kotliarov Y, Biancotto A, Xie Z, Germain RN, et al.
258 [Global analyses of human immune variation reveal baseline predictors of](#)
259 [postvaccination responses](#). *Cell*. 2014 Apr 10;157(2):499–513.
- 260 6. World Health Organization. SEROLOGICAL DIAGNOSIS OF INFLUENZA BY
261 MICRONEUTRALIZATION ASSAY. 2010; Available from:
262 [https://www.who.int/publications/i/item/serological-diagnosis-of-influenza-by-](https://www.who.int/publications/i/item/serological-diagnosis-of-influenza-by-microneutralization-assay)
263 [microneutralization-assay](#)
- 264 7. Loes AN, Tarabi RAL, Huddleston J, Touyon L, Wong SS, Cheng SMS, et al.
265 [High-throughput sequencing-based neutralization assay reveals how repeated](#)
266 [vaccinations impact titers to recent human H1N1 influenza strains](#). *bioRxiv: The Preprint*
267 *Server for Biology*. 2024 Mar 9;2024.03.08.584176.
- 268 8. World Health Organization. Manual for the laboratory diagnosis and virological
269 surveillance of influenza. WHO global influenza surveillance network: manual for the
270 laboratory diagnosis and virological surveillance of influenza [Internet]. 2011; Available
271 from: <https://iris.who.int/handle/10665/44518>
- 272 9. Lin YP, Gregory V, Collins P, Kloess J, Wharton S, Cattle N, et al.
273 [Neuraminidase receptor binding variants of human influenza A\(H3N2\) viruses resulting](#)
274 [from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment?](#)
275 *Journal of Virology*. 2010 Jul;84(13):6769–81.
- 276 10. Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. [AZD1222-](#)
277 [induced neutralising antibody activity against SARS-CoV-2 Delta VOC](#). *Lancet (London,*
278 *England)*. 2021 Jul 17;398(10296):207–9.
- 279 11. Carr EJ, Dowgier G, Greenwood D, Herman LS, Hobbs A, Ragno M, et al.
280 [SARS-CoV-2 mucosal neutralising immunity after vaccination](#). *The Lancet Infectious*
281 *Diseases*. 2023 Dec 6;
- 282 12. Shawe-Taylor M, Greenwood D, Hobbs A, Dowgier G, Penn R, Sanderson T, et
283 al. [Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster](#)
284 [campaign](#). *Lancet (London, England)*. 2024 Mar 11;

It is made available under a [CC-BY 4.0 International license](#) .

influenza HAI vs HTS

- 285 13. Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, et al.
286 Welcome to the tidyverse. Journal of Open Source Software [Internet]. 2019 Nov
287 21;4(43):1686. Available from: <http://dx.doi.org/10.21105/joss.01686>
- 288 14. Couch S, Bray A, Ismay C, Chasnovski E, Baumer B, Çetinkaya-Rundel M. Infer:
289 An r package for tidyverse-friendly statistical inference. Journal of Open Source
290 Software [Internet]. 2021 Sep 16;6(65):3661. Available from:
291 <https://joss.theoj.org/papers/10.21105/joss.03661>
- 292

influenza HAI vs HTS



Fig 1. Serological vaccination responses quantified by haemagglutinin inhibition and high-throughput live influenza neutralisation assays in the AgeVax study (A) AgeVax study design 73 individuals >65yo were vaccinated with adjuvanted quadrivalent influenza vaccine in the 2021-22 Northern Hemisphere season. **(B & C)** Haemagglutinin inhibition assay titres (HAI, **B**) or live-virus microneutralisation assay titres (LV-N, **C**), expressed as the reciprocal of the dilution at which 50% of virus infection is inhibited (IC_{50}), at baseline (d0), and days 7 and 182 after vaccination (d7 & d182, respectively) for the flu viruses listed. **(D)** \log_2 fold changes for peak (d7/d0) and wane (d182/d7) response as measured by HAI or LV-N (plotted as squares or circles respectively). Bootstrapped 95% confidence intervals are shown. In (B & C), crosses indicate geometric means, and P values from 2-tailed paired Wilcoxon signed rank tests are shown. In (C), diamonds indicate medians.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

influenza HAI vs HTS




Fig 2. Comparison of haemagglutinin inhibition and high-throughput live influenza neutralisation assays (A) Correlation between HAI and LV-N for each flu virus tested, at each venepuncture. In (A), Spearman correlation coefficients and *P* values are shown, and a fit line from linear regression plotted.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

influenza HAI vs HTS




Fig 3. Pre-existing antibody inhibits subsequent vaccine responses (A & B) Log₂ fold changes of peak titres (d7/d0) plotted against d0 titres for HAI (A) or LV-N (B). In (A & B), Spearman correlation coefficients and *P* values are shown, and a fit line from linear regression plotted.

It is made available under a [CC-BY 4.0 International license](#) .

influenza HAI vs HTS

296 **Table 1**

| Characteristic | AgeVAX, N = 73 ¹ |
|----------------|-----------------------------|
| Age | 70.0 [68.0-74.0] |
| Sex | |
| F | 35 (48%) |
| M | 38 (52%) |

¹Median [25%-75%]; n (%)

297